We are live on ! Find out more
ATYR

aTyr Pharma
ATYR

25 hedge funds and large institutions have $18.5M invested in aTyr Pharma in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 2

0% more funds holding

Funds holding: 25 → 25 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

1.86% less ownership

Funds ownership: 59.86% → 58% (-1.9%)

25% less capital invested

Capital invested by funds: $24.9M → $18.5M (-$6.33M)

Holders
25
Holders Change
–
Holders Change %
0%
% of All Funds
0.5%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
10
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
+$358K
2
Renaissance Technologies
Renaissance Technologies
New York
+$175K
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$109K
4
Millennium Management
Millennium Management
New York
+$93.5K
5
Two Sigma Investments
Two Sigma Investments
New York
+$83.6K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$158K
2
JMPWA
JP Morgan Private Wealth Advisors
California
-$100K
3
OC
Oppenheimer & Co
New York
-$81K
4
Citadel Advisors
Citadel Advisors
Florida
-$53K
5
Morgan Stanley
Morgan Stanley
New York
-$9.99K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$5.22M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$4.53M – – –
Alyeska Investment Group
3
Alyeska Investment Group
Illinois
$2.43M +$109K +26,662 +4%
Viking Global Investors
4
Viking Global Investors
Connecticut
$1.9M – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$1.32M +$175K +42,600 +12%
Vanguard Group
6
Vanguard Group
Pennsylvania
$755K +$48.9K +11,912 +5%
Two Sigma Advisers
7
Two Sigma Advisers
New York
$543K +$358K +87,300 +108%
Two Sigma Investments
8
Two Sigma Investments
New York
$492K +$83.6K +20,351 +15%
PVMCV
9
Polaris Venture Management Co V
Massachusetts
$422K – – –
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$269K +$62K +15,088 +22%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$148K – – –
BlackRock
12
BlackRock
New York
$134K +$32.6K +7,948 +24%
Ensign Peak Advisors
13
Ensign Peak Advisors
Utah
$122K – – –
Northern Trust
14
Northern Trust
Illinois
$67K – – –
AAP
15
Ardsley Advisory Partners
Connecticut
$65K +$82.1K +20,000 New
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$62K +$10.3K +2,500 +15%
MAM
17
Marquette Asset Management
Minnesota
$61K – – –
UBS Group
18
UBS Group
Switzerland
$5K -$158K -38,412 -96%
Morgan Stanley
19
Morgan Stanley
New York
$4K -$9.99K -2,433 -65%
TRCT
20
Tower Research Capital (TRC)
New York
$4K +$4.18K +1,019 New
Millennium Management
21
Millennium Management
New York
$74 +$93.5K +22,771 New
JMPWA
22
JP Morgan Private Wealth Advisors
California
– -$100K -22,579 Closed
OC
23
Oppenheimer & Co
New York
– -$81K -18,343 Closed
Citadel Advisors
24
Citadel Advisors
Florida
– -$53K -11,998 Closed
PAG
25
Private Advisor Group
New Jersey
– -$8K -1,736 Closed
1
2

ATYR Hedge Fund Activity: Q3 2020 in Review

25 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q3 2020, worth a combined $18.5M — down 25% from $24.9M a quarter earlier.

Fund positioning in ATYR was balanced in Q3 2020: 4 funds opened new positions, 4 closed out, 10 added to existing stakes and 2 trimmed.

The largest buyer was Two Sigma Advisers, adding an estimated $358K. The largest seller was UBS Group, cutting an estimated $158K.

  • 25 institutional investors held aTyr Pharma (ATYR) as of Q3 2020, unchanged from Q2 2020.
  • Funds reported $18.5M of aTyr Pharma stock for Q3 2020, down 25% quarter-over-quarter.
  • 4 funds opened new aTyr Pharma positions in Q3 2020 and 4 closed out, a net change of 0 holders.
  • The largest aTyr Pharma buyer in Q3 2020 was Two Sigma Advisers, an estimated $358K added.
  • The largest aTyr Pharma seller in Q3 2020 was UBS Group, an estimated $158K sold.

Based on aggregated 13F filings for Q3 2020.